[1]Patent:WO2006/55951,2006,A2,.Locationinpatent:Page/Pagecolumn66
[2]Patent:WO2006/63113,2006,A2,.Locationinpatent:Page/Pagecolumn126-127
[3]Patent:US2787617,1955,,
[1]Patent:US2005/222166,2005,A1,.Locationinpatent:Page/Pagecolumn13
[2]TetrahedronLetters,1994,vol.35,#51,p.9545-9548
[3]Patent:WO2006/51851,2006,A1,.Locationinpatent:Page/Pagecolumn80
[4]JournaloftheAmericanChemicalSociety,1940,vol.62,p.1202
[1]JournalofPorphyrinsandPhthalocyanines,2010,vol.14,#3,p.284-292
[2]TetrahedronLetters,2017,vol.58,#51,p.4750-4754
[1]Patent:CN104277040,2016,B,.Locationinpatent:Paragraph0159-0160
[2]AngewandteChemie,InternationalEdition,2015,vol.54,#1,p.179-183
[3]AngewandteChemie,2015,vol.127,#1,p.181-185,5
[1]Patent:WO2006/55951,2006,A2.Locationinpatent:Page/Pagecolumn66
[2]Patent:WO2006/63113,2006,A2.Locationinpatent:Page/Pagecolumn126-127
[3]Patent:US2787617,1955,
[1]JournalofMedicinalChemistry,1970,vol.13,p.846-848
[1]Patent:WO2005/117904,2005,A2.Locationinpatent:Page/Pagecolumn407
[2]Patent:WO2011/41713,2011,A2.Locationinpatent:Page/Pagecolumn147-148
[3]EuropeanJournalofMedicinalChemistry,2015,vol.101,p.218-235
[4]Patent:WO2006/72350,2006,A1.Locationinpatent:Page/Pagecolumn37
[5]Patent:WO2006/72353,2006,A1.Locationinpatent:Page/Pagecolumn30
[6]Patent:US2011/166121,2011,A1.Locationinpatent:Page/Pagecolumn32
[7]ChemicalCommunications,2019,vol.55,p.14351-14354
[8]Patent:EP1762568,2007,A1.Locationinpatent:Page/Pagecolumn57
[9]Patent:WO2005/14540,2005,A1.Locationinpatent:Page/Pagecolumn59
[10]Patent:WO2006/14762,2006,A1.Locationinpatent:Page/Pagecolumn37
[11]Patent:WO2006/14944,2006,A1.Locationinpatent:Page/Pagecolumn29
[12]Patent:US2018/127370,2018,A1.Locationinpatent:Paragraph0735;0733
[13]Patent:WO2005/16876,2005,A2.Locationinpatent:Page/Pagecolumn75-76
[14]Patent:EP1591443,2005,A1.Locationinpatent:Page/Pagecolumn63
[15]Patent:US6235731,2001,B1
[16]Patent:EP1621537,2006,A1.Locationinpatent:Page/Pagecolumn47;51-52
[17]Patent:EP1762568,2007,A1.Locationinpatent:Page/Pagecolumn36-37;57
[18]Patent:EP1785418,2007,A1.Locationinpatent:Page/Pagecolumn43;72
[19]Patent:EP1803719,2007,A1.Locationinpatent:Page/Pagecolumn39
[20]Patent:CN107098886,2017,A.Locationinpatent:Paragraph0147-0149
[21]Patent:EP1477490,2004,A1.Locationinpatent:Page109
[22]Patent:WO2017/117393,2017,A1.Locationinpatent:Page/Pagecolumn148
[23]Patent:WO2016/168619,2016,A1.Locationinpatent:Paragraph00291
[24]TetrahedronLetters,1980,vol.21,p.3019-3020
[25]Patent:WO2004/35576,2004,A2.Locationinpatent:Page172;173
[26]Patent:US2003/109559,2003,A1
[27]Patent:US6403595,2002,B1
[28]Patent:US5629322,1997,A
[29]Patent:US4341698,1982,A
[30]BioorganicandMedicinalChemistryLetters,2008,vol.18,p.3236-3241
[31]Patent:EP1188755,2002,A1.Locationinpatent:Page42
[32]Patent:WO2013/134226,2013,A1.Locationinpatent:Page/Pagecolumn94
[33]Patent:US2013/236468,2013,A1.Locationinpatent:Paragraph0333
[34]Patent:WO2014/100716,2014,A1.Locationinpatent:Paragraph00222
[35]Patent:WO2015/150555,2015,A1.Locationinpatent:Page/Pagecolumn151
[36]Patent:WO2007/8144,2007,A1.Locationinpatent:Page/Pagecolumn27
[37]Patent:CN108610332,2018,A.Locationinpatent:Paragraph0133;0135;0136;0168
[38]Patent:CN108610333,2018,A.Locationinpatent:Paragraph0132;0134;0135
[39]Patent:CN109867660,2019,A.Locationinpatent:Paragraph0383-0384
[1]Arzneimittel-Forschung/DrugResearch,1986,vol.36,p.1545-1549
[1]JournalofMedicinalChemistry,1980,vol.23,p.1358-1363
[2]Patent:US4448962,1984,A
Title: Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency.
Journal: Bioorganic & medicinal chemistry letters 20120115
Title: Identification of novel sildenafil-analogues in an adulterated herbal food supplement.
Journal: Journal of pharmaceutical and biomedical analysis 20111205
Title: Discovery of potent, orally bioavailable phthalazinone bradykinin B1 receptor antagonists.
Journal: Journal of medicinal chemistry 20111027
Title: Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Journal: Bioorganic & medicinal chemistry letters 20110615
Title: 3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.
Journal: Bioorganic & medicinal chemistry letters 20110601
Title: A submarine journey: the pyrrole-imidazole alkaloids.
Journal: Marine drugs 20091201
Title: Ligand scaffold hopping combining 3D maximal substructure search and molecular similarity.
Journal: BMC bioinformatics 20090101
Title: Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines.
Journal: Journal of asthma and allergy 20090101
Title: Computer applications for prediction of protein-protein interactions and rational drug design.
Journal: Advances and applications in bioinformatics and chemistry : AABC 20090101
Title: Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.
Journal: Journal of medicinal chemistry 20081009
Title: Concise synthesis of the CDE ring system of tetrahydroisoquinoline alkaloids using carbophilic Lewis acid-catalyzed hydroamidation and oxidative Friedel-Crafts cyclization.
Journal: The Journal of organic chemistry 20080704
Title: Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20080601
Title: Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers.
Journal: Bioorganic & medicinal chemistry 20080201
Title: [Piperazines as model substrate for oxidations].
Journal: Die Pharmazie 20061001
Title: New class of nucleophiles for palladium-catalyzed asymmetric allylic alkylation. Total synthesis of agelastatin A.
Journal: Journal of the American Chemical Society 20060510
Title: Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I.
Journal: Organic & biomolecular chemistry 20060507
Title: (13)C NMR spectral assignment of 1,4-diarylpiperazinones.
Journal: Magnetic resonance in chemistry : MRC 20060101
Title: Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Effect of ring opening of piperazinone moiety on inhibition.
Journal: Chemical & pharmaceutical bulletin 20040401
Title: Macrocyclic piperazinones as potent dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
Journal: Bioorganic & medicinal chemistry letters 20040209
Title: Synthesis of a library of 3-oxopiperazinium and perhydro-3-oxo-1,4-diazepinium derivatives and identification of bioactive compounds.
Journal: Journal of combinatorial chemistry 20040101
Title: alpha-Keto amides as precursors to heterocycles--generation and cycloaddition reactions of piperazin-5-one nitrones.
Journal: Organic & biomolecular chemistry 20030407
Title: Synthesis of 1,4-diazines by ring expansion of 1,3-diazines.
Journal: The Journal of organic chemistry 20030321
Title: Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.
Journal: Journal of medicinal chemistry 20030227
Title: Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: synthesis and pharmacological evaluation of 2-oxopiperazine derivatives.
Journal: Journal of medicinal chemistry 20010719
Title: The design of competitive, small-molecule inhibitors of coagulation factor Xa.
Journal: Current topics in medicinal chemistry 20010601
Title: 3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics: synthesis of a conformationally restricted inhibitor of farnesyltransferase.
Journal: Organic letters 20010322
Title: Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase.
Journal: Bioorganic & medicinal chemistry letters 20010226
Title: Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20010212
